XKRX
083790
Market cap53mUSD
Oct 08, Last price
930.00KRW
1D
2.31%
1Q
3.45%
Jan 2017
-92.73%
IPO
-92.53%
Name
CrystalGenomics Inc
Chart & performance
P/E
—
P/S
2.61
EPS
—
Div yield, %
—
Shrs. gr., 5y
-0.73%
Rev. gr., 5y
-1.95%
Revenues
27.39b
+277.64%
Net income
-3.52b
L-93.17%
CFO
-17.41b
L-32.64%
Dividend
Mar 15, 20220.285 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CG Invites Co., Ltd., based in Seoul, South Korea, specializes in the groundbreaking discovery and progression of novel medical treatments. Founded on July 7, 2000, by Cho Joong Myung and Ro Seong Gu, the company's operations are divided into two main areas. Its Pharmaceutical Research and Development segment primarily focuses on utilizing digital genomics for drug innovation. Additionally, the Automation Equipment division is responsible for manufacturing machinery, including hot pack and printed circuit board (PCB) equipment.
Key people
Yin Cheol Jung
Co-Chief Executive Officer, Director · since 2024
Su Yeon Oh
Co-Chief Executive Officer, Director · since 2024
Yeong Jun Yoo
Internal Auditor · since 2021
Director
Seung Hyeon Choi
Director · since 2021
Jin Gon Kim
Director
Yong Gyu Shin
Director · since 2023
Jin Wu Lee
Non-Executive Independent Director
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑08 | 2017‑08 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||